20080909
 Sanofi Turns to Glaxo Official; French Drug Maker Picks Viehbacher For a Senior Post   By Elena Berton and Jeanne Whalen, The Wall Street Journal,  Sep 10, 2008  Among the setbacks: brief but damaging generic competition in the U.S. to one of the company's biggest drugs, the blood thinner Plavix; generic competition to Plavix in Germany; and the failure to get big new products, such as Acomplia for obesity and Multaq for heart disease, approved in the U.S. "The stock has been besieged by a series of negative surprises in the last two to three years, and there are questions among some investors about whether theses issues could have been better managed," says Gbola Amusa, a pharmaceutical analyst at UBS in London.   
